XNW29016

Evopoint Biosciences Inc. · Phase 1 active Small molecule

At a glance

Generic name	XNW29016
Also known as	PARGi
Sponsor	Evopoint Biosciences Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XNW29016 CI brief — competitive landscape report
XNW29016 updates RSS · CI watch RSS
Evopoint Biosciences Inc. portfolio CI